Duchesne G M
Department of Oncology, University College and Middlesex School of Medicine, Middlesex Hospital, London, UK.
Lung Cancer. 1994 Mar;10 Suppl 1:S67-72. doi: 10.1016/0169-5002(94)91668-3.
This overview briefly examines the mechanisms of drug resistance in lung cancer, including multidrug resistance and its atypical phenotypes, the role of cytoplasmic protectors such as glutathione, and resistance at the level of the DNA through topoisomerases, gene amplification or mutation, and DNA repair. Understanding of radioresistance is less advanced, but resistance may arise through limitation of the amount of DNA damage inflicted or by its subsequent modification by intracellular protectors or DNA repair. The mechanisms of radioresistance are generally distinct from those of chemoresistance providing a rationale for the use of combined modality therapy.
本综述简要探讨了肺癌耐药的机制，包括多药耐药及其非典型表型、细胞质保护剂（如谷胱甘肽）的作用，以及通过拓扑异构酶、基因扩增或突变和DNA修复在DNA水平上的耐药。对放射抗性的理解尚不够深入，但抗性可能是由于所造成的DNA损伤量有限，或由于细胞内保护剂或DNA修复对其随后的修饰而产生的。放射抗性机制通常与化学抗性机制不同，这为联合治疗模式的应用提供了理论依据。
